Thanks to complex manufacturing, Novartis expects blockbuster Sandostatin LAR to steer clear of generics in 2020

3rd February 2020 Uncategorised 0

Novartis’ Sandostatin LAR has been on the U.S. market for more than two decades, but the company still doesn’t expect copycat competition this year. Why? It’s tough to manufacture, and that’s kept generics at bay. But the Swiss drugmaker might just get a surprise from Teva before 2020 is out.

More: Thanks to complex manufacturing, Novartis expects blockbuster Sandostatin LAR to steer clear of generics in 2020
Source: fierce